PROLOR Biotech to Present at Jefferies and Co. 2012 Global Health Care Conference

NES-ZIONA, Israel, May 30, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), a clinical stage company developing next generation biobetter therapeutic proteins, today announced that company management will give a corporate presentation at the Jefferies 2012 Global Health Care Conference, being held at the Grand Hyatt Hotel in New York City. The presentation is scheduled for June 5, 2012 at 3:00 pm ET.

A live webcast of the company’s presentation will be available at the Investors section of PROLOR’s website at www.prolor-biotech.com/?CategoryID=215, or at http://wsw.com/webcast/jeff68/pbth/. An audio replay of the presentation will be available on the PROLOR website approximately one hour after the presentation and will be archived for at least 30 days.

For more information about the Jefferies 2012 Global Health Care Conference, visit http://www.jefferies.com/cositemgr.pl/html/OurFirm/ConferencesEvents/upcoming/20120604GlobalHealth.shtml.

ABOUT PROLOR
PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins. PROLOR is currently developing a long-acting version of human growth hormone, which has successfully completed a Phase II clinical trial. It also is developing long-acting versions of Factor VIIa and Factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and obesity, as well as agents for atherosclerosis and rheumatoid arthritis, which are all in preclinical development. For more information, visit www.prolor-biotech.com.

SOURCE PROLOR Biotech, Inc.